Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

Toni K. Choueiri, Bernard J. Escudier, Thomas B. Powles et al. · The Lancet Oncology · 2016

Cited by 958 works. doi:10.1016/s1470-2045(16)30107-3

Authors

References